Ovarian cancer is one of the most common malignancies in women worldwide. Unlike breast cancer, ovarian cancer lacks early diagnostic markers and does not show noticeable symptoms until cancer metastases, leading to a low survival rate for ovarian cancer patients.
Engineered exosome-based drug delivery system shows promise for ovarian cancer therapy retrieved 12 August 2024 from https://medicalxpress.com/news/2024-08-exosome-based-drug-delivery-ovarian.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
Medicine Research Health Research News Health Research Health Science Medicine Science
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novel neutrophil-engineered nanovesicles could transform infectious wound treatmentA recent study has developed nanovesicles (NVs) from activated neutrophils, showcasing their ability to perform molecular debridement and accelerate healing in infectious wounds.
Read more »
FDA grants accelerated approval for first engineered T cell therapy to treat adults with synovial sarcomaThe U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called synovial sarcoma.
Read more »
FDA approves engineered cell therapy for treating rare sarcomaThe U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleuecel (Tecelra, also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called synovial sarcoma.
Read more »
Engineered NK cells with IL-21 show strong antitumor activity against glioblastomaNatural killer (NK) cells engineered to express interleukin-21 (IL-21) demonstrated sustained antitumor activity against glioblastoma stem cell-like cells (GSCs) both in vitro and in vivo, according to new research from The University of Texas MD Anderson Cancer Center.
Read more »
Salpingectomy during sterilization can be a safe option to reduce ovarian cancer riskWomen whose Fallopian tubes are removed during sterilization via laparoscopy have only marginally more surgical complications than those whose tubes are simply cut, a study shows.
Read more »
Novel approach to study hypoxia enables identification of a marker for ovarian cancersIn a new study, the team led by Étienne Gagnon, Professor in the Department of Microbiology, Infectious Diseases and Immunology at the Université de Montréal and Director of IRIC's Cancer Immunobiology Research Unit, has developed a cell culture protocol that accurately reproduces the characteristic conditions of primary tumors.
Read more »